Menu
Washingtoner
  • Home
  • Artificial Intelligence
  • Health
  • Technology
  • Entertainment
  • Software
  • Real Estate
  • Business
  • Education
Washingtoner

Lineus Medical Announces a Reduction in Price for SafeBreak Vascular
Washingtoner/10268034

Trending...
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
SafeBreak Vascular Lineus Medical
FAYETTEVILLE, Ark. - Washingtoner -- Lineus Medical announces a significant reduction in price of nearly 15% for its flagship product, SafeBreak Vascular, in the United States. After creating a new device classification with the FDA and becoming the first break-away device available for IV lines in the US, SafeBreak Vascular was first released with a list price of $6.90. Since its release, increased sales volume and concentrated efforts toward manufacturing efficiencies support a price adjustment with a new list price of $5.90, effective on September 1st, 2024.

SafeBreak Vascular is the only break-away device for IV lines proven to reduce IV complications1.  When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.

More on Washingtoner
  • The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Jamie Foxx's SKVLK Fest Sets the Record Straight on Stabbing Reports Following Star-Studded Celebration

"A large focus of our strategy is maximizing our economic value proposition for the hospital." Lineus Medical's Vice President of Sales, Larry Hayes comments, "Reducing our price allows for both current and new accounts to take advantage of cost savings, and in doing so, we are making it easier for hospitals to invest in improved vascular access care for their patients."

Vance Clement, CEO of Lineus Medical, stated, "Inflation is hitting everyone, and we are all used to prices going up.  This is especially true in healthcare, where prices never go down. However, SafeBreak, which is proudly made in the USA, is changing that. As we continue to grow, we will keep investing in manufacturing so that we can lower the cost of SafeBreak again in the future."

Lineus Medical is committed to improving patient safety and advancing vascular access care and believes that this price reduction is another important step in our mission to remove the pains associated with medical lines.  Anyone interested in SafeBreak Vascular's price reduction can visit our website www.lineusmed.com to learn more.

About Lineus Medical

Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn.

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical
Filed Under: Health, Technology

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • HIRO Ostomy Belt Launch by Richard O'Hamill
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Flags Lowered for Spokane County Sheriff Deputies
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
  • ARADIA (Est. 1991) Launches First B2A Partner Program for AI
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • Spokane: Drugs and Guns Seized in a Counter Narcotics Investigation
  • Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
  • The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
  • Spokane: City and County Issue Joint Housing and Homelessness Funding RFP
  • Spokane: Council Approves Additional Funding to Prepare for Inclement Weather
  • Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
  • Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
  • ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
  • Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
  • Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
  • PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
  • Spokane: City And County Seek Federal Grant to Plan for Road Network Wildfire Resilience
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 248
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 214
  • Final Week to Register for Free Spokane Community Conference - 189
  • Citizens for West Virginia Election Integrity Urges "FOR" on Amendment 1 - 178
  • Author Robert A. Robinson Introduces Anarchy at the AYP: - 138
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 130
  • Kent Youth and Family Services Announces Sale of Watson Manor - 117
  • Simpalm Staffing Launches Tax Preparer Staffing for U.S. CPA Firms - 112
  • Meta Partnership Expanding as Omni One Orders Surge 3X -New Consumer Bundles, Defense Opportunities & AI Robotics: Virtuix Holdings: N A S D A Q: VTIX - 111
  • Self-Published Dad's Santa Book Finally Found After 3 Years on Amazon

Similar on Washingtoner

  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
  • Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
  • New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
  • Qscription Technologies Welcomes Joanna Krause, MD, MRMD to Its Clinical Advisory Board
  • Romanian Software Company ASSIST Software Ranks Second Nationally Among Large Enterprises in Its Category
  • Washington Nurse Introduces Nightingale Care Hub to Help Families Organize Care
  • New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
  • Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute